Malignant Rhabdoid Tumor

What is a malignant rhabdoid tumor?

Malignant rhabdoid tumor is a rare childhood tumor that commonly starts in the kidneys but also can occur in other soft tissues or in the brain, where it is referred to asatypical teratoid rhabdoid tumor (ATRT).

These tumors occur most commonly in infants and toddlers; the average age of diagnosis is 15 months old. There are about 20 to 25 new cases of malignant rhabdoid tumor diagnosed each year in the United States. Cells from malignant rhabdoid tumors in children can spread (metastasize) to other areas of the body.

How we care for malignant rhabdoid tumors

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is a world-leading center in the research and treatment of rhabdoid tumors. Our vibrant program of basic and translational research into rhabdoid tumors is uncovering new opportunities to improve the care of children with this diagnosis. Our multidisciplinary treatment approach ensures in-depth discussion of each child and personalized treatment plans for every patient.

What is the latest research for malignant rhabdoid tumor?

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center are global leaders in the basic and translational study of rhabdoid tumors. Their goal is to understand the biological basis of rhabdoid tumors, including the role(s) of mutations in the gene SMARCB1, and to develop more effective treatment methods for children with these tumors.

In addition, we have a phase I clinical trial open for children with refractory or relapsed malignant rhabdoid tumor, as well as access to any malignant rhabdoid tumor trials available through the Children's Oncology Group.

For many children with rare or hard-to-treat conditions, clinical trials provide new options.